Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Cyclic peptide interleukin-1 beta traps: MerckRecent Research Landscape

Uncontrolled interleukin-1 beta signaling drives chronic inflammatory tissue damage, which is mitigated through the engineering of conformationally constrained cyclic peptide architectures that sequester the cytokine. This structural rigidity enhances binding affinity and metabolic stability compared to linear variants.

What technical problems is Merck addressing in Cyclic peptide interleukin-1 beta traps?

Excessive systemic cytokine signaling

(12)evidences

Uncontrolled bioactivity of interleukin-1 beta drives chronic inflammatory pathology. Neutralizing this specific ligand prevents aberrant receptor activation and tissue damage.

Pathological cytokine receptor signaling

(4)evidences

Uncontrolled signaling through the TNF receptor 1 pathway leads to chronic inflammatory tissue damage. Inhibiting this specific interaction prevents systemic cytokine-mediated toxicity.